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Abstract
Background: Type 2 diabetes mellitus is associated
with increased cardiovascular risk. One laboratory
marker for cardiovascular risk assessment is high-
sensitivity C-reactive protein (hsCRP).
Methods: This cross-sectional study attempted to
analyze the association of hsCRP levels with insulin
resistance, b-cell dysfunction and macrovascular dis-
ease in 4270 non-insulin-treated patients with type 2
diabetes w2146 male, 2124 female; mean age "SD,
63.9"11.1 years; body mass index (BMI) 30.1"5.5
kg/m2; disease duration 5.4"5.6 years; hemoglobin
A1c (HbA1c) 6.8"1.3%x. It consisted of a single morn-
ing visit with collection of a fasting blood sample.
Observational parameters included several clinical
scores and laboratory biomarkers.
Results: Stratification into cardiovascular risk groups
according to hsCRP levels revealed that 934 patients
had low risk (hsCRP -1 mg/L), 1369 patients had
intermediate risk (hsCRP 1–3 mg/L), 1352 patients had
high risk (hsCRP )3–10 mg/L), and 610 patients had
unspecific hsCRP elevation ()10 mg/L). Increased
hsCRP levels were associated with other indicators of
diabetes-related cardiovascular risk (homeostatic
model assessment, intact proinsulin, insulin, BMI, b-
cell dysfunction, all p-0.001), but showed no corre-
lation with disease duration or glucose control. The
majority of the patients were treated with diet (34.1%;
hsCRP levels 2.85"2.39 mg/L) or metformin mono-
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therapy (21.1%; 2.95"2.50 mg/L hsCRP). The highest
hsCRP levels were observed in patients treated with
sulfonylurea (17.0%; 3.00"2.43 mg/L).
Conclusions: Our results indicate that hsCRP may be
used as a cardiovascular risk marker in patients with
type 2 diabetes mellitus and should be evaluated in
further prospective studies.
Keywords: high-sensitivity C-reactive protein (hsCRP);
homeostatic model assessment (HOMA); insulin
resistance; intact proinsulin; type 2 diabetes.
Introduction
Patients with type 2 diabetes suffer from high cardio-
vascular morbidity and mortality based on extensive
and accelerated arteriosclerosis (1). Coronary arterio-
sclerosis is increasingly recognized as a major com-
plication and the leading cause of death in subjects
with diabetes (2). It has been shown by laboratory and
experimental studies that arteriosclerosis, as well as
being a disease of lipid accumulation, represents a
chronic inflammatory process (3). Thus, inflammatory
markers have been investigated to identify potential
adjunctive predictors for global assessment of cardio-
vascular risk (4–6). Several large-scale prospective
epidemiological studies have demonstrated that high-
sensitivity C-reactive protein (hsCRP) is a strong inde-
pendent predictor for risk of future myocardial
infarction and other consequences of arteriosclerosis,
even in patients without known macrovascular dis-
ease (7–10). With the recognition that inflammation is
a critical component in the determination of plaque
stability, CRP levels in the low–normal range were
found to have predictive value for patients with acute
coronary ischemia (11, 12). Levels of hsCRP -1 mg/L,
1–3 mg/L and )3 mg/L have been suggested to define
low-, moderate-, and high-risk groups, while levels
)10 mg/L may indicate unspecific elevation conse-
quent to a general inflammatory process (9).
In this analysis of the IRIS-II study population
(13–15), we investigated the prevalence of hsCRP in
a large population of 4270 orally treated type 2 dia-
betes mellitus patients, and its correlation with the
prevalence of insulin resistance, b-cell dysfunction
and cardiovascular events.
Patients and methods
The epidemiological cross-sectional study was performed in
German patients with orally treated type 2 diabetes mellitus
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Table 1 Clinical and laboratory results for patients in the different b-cell dysfunction stages.
Parameter b-Cell dysfunction stage
I II III
n 1042 1658 1570
Gender, female/male 501/538 746/912 899/672
Age, years 65"12 64"11** 65"11*
Disease duration, years 5.5"6.1 5.1"5.5 5.4"5.2
BMI, kg/m2 27.2"4.4 30.5"5.2*** 30.9"5.3***
Macrovascular disease, % 25.0 23.5 31.1
Hypertension, % 12.1 14.8 17.3
Neuropathy, % 12.2 14.8 17.3
Retinopathy, % 5.6 5.7 7.1
Nephropathy, % 16.0 14.9 21.2
HOMA score, mUŸmmol/L
2 1.38"0.39 3.66"2.22*** 6.61"5.36***
HbA1c, % 6.3"0.9 6.7"1.2*** 7.1"1.3***
hsCRP (not BMI-adjusted), mg/L 4.0"7.4 5.5"12.3*** 6.8"14.0***
Insulin, mU/mL 6.1"2.0 13.5"7.1*** 20.4"13.3***
Glucose, mmol/L 5.3"1.2 6.6"1.7*** 7.0"1.7***
Intact proinsulin, pmol/L 4.3"2.0 6.1"2.1*** 22.1"15.8***
Triglyerides, mmol/L 1.45"1.65 1.88"1.48*** 2.31"1.74***
HDL, mmol/L 1.3"0.35 1.20"0.33*** 1.08"0.28***
LDL, mmol/L 3.13"0.83 3.23"0.83 3.18"0.8
*p-0.05; **p-0.01; ***p-0.001 vs. stage I. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
in accordance with Good Clinical Practice and the Declara-
tion of Helsinki. The participants completed a standardized
questionnaire, and blood samples were drawn in the fasting
state. Actual therapy and the prevalence of microvascular
(retinopathy, nephropathy, neuropathy) and macrovascular
(stroke, coronary and peripheral artery disease, myocardial
infarction) disease was assessed by an examination and col-
lection of a detailed medical history. All laboratory data were
measured in a central laboratory. Hemoglobin A1c (HbA1c)
was measured by HPLC (Menarini, Neuss, Germany; refer-
ence range 4.4–6.0%). Glucose was determined using a glu-
cose oxidase method (SuperGL; Ruhrtal Labortechnik,
Delecke-Mo¨hnesee, Germany). Insulin and intact proinsulin
were determined by means of specific immunoassays (Scie-
ma, Mainz, Germany) as previously published (16). HsCRP
was assessed by means of a turbidimetric method (Olym-
pus, Hamburg, Germany).
Assessment of insulin resistance was performed by anal-
ysis of fasting intact proinsulin values or homeostatic model
assessment (HOMAIR) score calculation. Patients with intact
proinsulin values exceeding the normal reference value of
11 pmol/L were considered to be insulin-resistant (14, 15). In
the case of normal intact proinsulin values, HOMAIR score
calculation was applied, as previously published (17). The
estimate of insulin resistance by HOMAIR score was calcu-
lated using the following formula: fasting serum insulin
(mU/mL)=fasting plasma glucose (mmol/L)/22.5. As
described by Hedblad et al. in a non-diabetic population,
patients with HOMAIR score values exceeding the 75th per-
centile (i.e., 2.0) were considered to have insulin resistance
(18). The b-cell dysfunction stage was assessed by consid-
ering steady state of insulin and intact proinsulin on the fast-
ing morning, as previously reported (19).
Statistical analysis
As hsCRP has been reported to be associated with body
mass index (BMI), hsCRP concentrations were adjusted for
BMI before further analysis (20). To compare the means of
the variables measured, Student’s t-test, and theMann-Whit-
ney U-test were used. All tests were carried out as two-sided.
Results with p-values less than 0.05 were considered statis-
tically significant. All calculations were made with the SPSS
statistical package (version 9.0; SPSS Inc., Chicago, IL, USA).
Results
The study was completed by 2146 male and 2124
female patients with type 2 diabetes on oral medica-
tion and/or diet wage (mean"SD) 63.9"11.1 years
(range 21–96); disease duration 5.4"5.6 years (range
0–52); BMI 30.1"5.5 kg/m2 (range 16.0–67.2); waist/
hip ratio 1.0"0.1 (range 0.6–1.4); HbA1c 6.8"1.3%
(range 4.2–16.0%)x. No significant differences in de-
mographic data could be observed between male and
female patients.
Stratification of the patients into the different b-cell
dysfunction stages, as previously defined (19), led to
the following results: stage I (no insulin resistance or
b-cell secretion disorder), 1042 patients (24.4%); stage
II (insulin resistance without secretion disorder), 1658
patients (38.8%); and stage III (insulin resistance and
secretion disorder), 1570 patients (36.7%). The clinical
characteristics of these groups are given in Table 1.
Calculation of the mean hsCRP concentration in all
three b-cell dysfunction groups revealed high risk lev-
els for all stages of b-cell dysfunction. A higher car-
diovascular risk was associated with more advanced
stages of b-cell dysfunction (p-0.001), as shown in
Figure 1.
Stratification of the patients into the hsCRP risk
groups as suggested by Ridker and Cook (9) revealed
that 934 patients had low risk (hsCRP -1 mg/L,
21.8%), 1369 patients were in the medium-risk group
(hsCRP 1–3 mg/L, 32.0%), and 1352 patients were in
the high-risk group (hsCRP )3–10 mg/L, 31.6%). The
number of patients with unspecific elevated hsCRP
values ()10 mg/L) was 610 (14.3%).
The differences observed for both hsCRP-associat-
ed cardiovascular risk and severity of b-cell dysfunc-
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Figure 1 Stratification of patients (% distribution) with high and low cardiovascular risk (according to hsCRP risk group
definition) into the b-cell dysfunction stages as defined by Pfu¨tzner et al. (19). Higher cardiovascular risk is associated with a
higher degree of b-cell dysfunction.
Table 2 Clinical and laboratory results in the hsCRP risk groups.
Parameter Low risk Intermediate risk High risk p-Value for
(hsCRP -1 mg/L) (hsCRP 1–3 mg/L) (hsCRP )3–10 mg/L) correlation
n 934 1369 1352
Age, years 64"11 65"11 64"11 n.s.
Disease duration, years 6.3"6.5 5.4"5.3 5.1"5.3 n.s.
BMI, kg/m2 27.3"4.1 29.2"4.2 31.2"5.3 -0.001
HbA1c, % 6.59"1.10 6.73"1.16 6.95"1.32 n.s.
Fasting glucose, mmol/L 5.9"1.6 6.2"1.8 6.4"1.9 -0.05
Fasting insulin, mU/mL 10.9"9.0 13.2"9.6 15.3"11.5 -0.001
HOMAIR score, mUŸmmol/L
2 3.0"3.3 3.7"3.3 4.5"4.2 -0.001
Fasting intact proinsulin, pmol/L 8.7"8.2 13.2"9.6 15.3"11.5 -0.001
hsCRP (BMI-adjusted), mg/L 0.53"0.28 1.87"0.57 5.50"1.86 -0.001
Prevalence of macrovascular complication 208 (22.3%) 382 (27.9%) 383 (28.3%) -0.001
Prevalence of microvascular complications 260 (27.8%) 397 (29.0%) 406 (30.0%) -0.001
tion were independent of disease duration. A sum-
mary of the mean values for HbA1c, HOMAIR, hsCRP,
intact proinsulin, BMI, disease duration, and the prev-
alence of macrovascular disease in the hsCRP risk
groups is given in Table 2. It is evident that other well-
known cardiovascular risk indicators in type 2 diabe-
tes mellitus, such as BMI, insulin resistance and intact
proinsulin, are strongly correlated with the hsCRP
risk staging according to Ridker and Cook (7, 9), while
the correlation with markers of glucose metabolism
(HbA1c, glucose) is less pronounced, although still sig-
nificant because of the high number of patients.
The association of hsCRP values with prescribed
therapy is shown in Figure 2. Patients receiving com-
bination therapy of peroxisome proliferator activated
receptor g (PPARg) agonists with metformin present-
ed the lowest hsCRP mean values (p-0.05).
Discussion
The cross-sectional IRIS study was initially performed
to identify diagnostic parameters for insulin resis-
tance in non-insulin-treated patients with type 2 dia-
betes that are suitable for daily practice (13–15).
Analysis of the same patient population presented
here was performed to evaluate the correlation
between cardiovascular risk, as identified by hsCRP
risk assessment and b-cell dysfunction, and insulin
resistance. In our non-insulin-treated type 2 diabetes
patients with approximately 5 years of disease dura-
tion, the prevalence of macrovascular complications
was 20–30%. Serum levels of hsCRP were correlated
with the severity of insulin resistance and b-cell dys-
function. All analysis groups, however, had hsCRP
levels indicating high cardiovascular risk.
Chronic vascular inflammation may be the reason
why hsCRP was elevated in our type 2 diabetes pop-
ulation. Strong correlations were evident between
cardiovascular risk as assessed by hsCRP stratifica-
tion and other parameters that are associated with
increased risk or increased prevalence of cardiovas-
cular complications in patients with type 2 diabetes,
such as BMI, insulin resistance and elevated proin-
sulin (21–23). No or only weak associations, however,
were evident for age, disease duration and the met-
abolic markers HbA1c and fasting glucose. This result
is in line with previous reports demonstrating that
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Figure 2 hsCRP values (adjusted for BMI) in patients treated with different oral treatment regimens; SU, sulfonylurea; Metf,
metformin; TZD, thiazolidinediones; Glin, glinides; AGI, a-glucosidase inhibitors.
postprandial glucose, rather than fasting glucose
and HbA1c, is a strong predictor for cardiovascular
mortality in patients with type 2 diabetes, as it may
increase adhesion molecule secretion by endothelial
cells when glucose concentrations increase above
toxic levels (24).
A weakness of our study is the cross-sectional
approach, which does not allow conclusions to be
drawn about the impact of different therapeutic inter-
ventions on the metabolic and macrovascular risk
scenario. It has, however, been demonstrated that
impairment of b-cell dysfunction, as indicated by
increased intact proinsulin levels, is associated with
the use of insulinotropic substances, such as sulfo-
nylurea drugs (15). In this analysis the highest hsCRP
levels were also observed in patients receiving sul-
fonylurea therapy. These results support the hypo-
thesis that cardiovascular disease risk may be
associated with sulfonylurea treatment, as suspected
decades ago (25, 26) and reported again recently (27).
Unfortunately, contradicting reports from studies
such as the UK Prospective Diabetes Study (UKPDS)
did not involve well enough characterized patient
populations to allow direct comparison of the results
(28). However, prospective studies using the same
diagnostic markers as used in our current analysis
have provided evidence of a beneficial impact of other
therapeutic interventions compared to sulfonylurea
therapy. Treatment of insulin resistance, e.g., using
PPARg agonists seems to be an effective measure for
decreasing cardiovascular and metabolic risk (29–32).
The importance of determining hsCRP in at-risk
populations, such as diabetic patients, is further
strengthened by recent reports suggesting that hsCRP
is not only a risk indicator, but may also allow mon-
itoring of arteriosclerosis regression during success-
ful therapeutic interventions. Patients who have low
CRP levels after statin therapy have better clinical out-
comes than those with higher CRP levels, regardless
of the resultant level of LDL cholesterol (33). In the
‘‘Reversal of Atherosclerosis with Aggressive Lipid
Lowering’’ study (REVERSAL), the reduced rate of
progression of atherosclerosis associated with inten-
sive statin treatment, as compared with moderate
statin treatment, was significantly related to greater
reductions in the levels of both atherogenic lipopro-
teins and CRP in patients with coronary artery disease
(34). The same may hold true for patients with type 2
diabetes. Whether determination of hsCRP can pro-
vide additional risk information in type 2 diabetes,
similar to the analysis of Ridker et al. in the Framing-
ham Risk Score population (35), needs to be explored
in prospective epidemiological trials.
The results of our analysis indicate that impaired
insulin resistance and impaired b-cell function were
associated with higher hsCRP levels and a higher
prevalence of macrovascular complications. The clear
association between hsCRP and other established or
suspect risk markers support the suitability of hsCRP
as a cardiovascular risk marker suitable for routine
clinical use in type 2 diabetes mellitus.
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